Jesse McGreivy
Soleno Therapeutics (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma(2013)1,668 cited
- → Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia(2014)1,603 cited
- → Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma(2015)1,102 cited
- → Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia(2015)881 cited
- → A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer(2012)189 cited
- → The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study(2012)170 cited
- → Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial(2013)164 cited
- → Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies(2014)73 cited
- → Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer(2009)51 cited
- → Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)(2010)45 cited